Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ascendis Pharma A/S (ASND)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
95.40+4.27 (+4.69%)
At close: 04:00PM EDT
95.40 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Sign in to post a message.
  • I
    Illi
    ASND looks like trash today - I bet it falls from here. Glad I am signed up to (http://Achieverspot.tech) so that I can get stocks that actually move!
  • L
    Lookingforatenbagger
    Some thoughts on the note offering.
    1. 2.25% on $1/2B = $11.3M in interest per year or ~$0.20/share
    2. Net $485M received (bankers gotta get paid)
    3. ~120M of the net will be used to purchase 1M shares.
    4. Currently there are 57M shares outstanding, which is reduced to 56M, a 1.8% reduction.
    5. At the current conversion price 3M new shares will be issued to retire the debt.
    6. ASND has $682M in cash (according to Yahoo) Now. Total of $1,17 billion after offering
    7. ASND's current debt is $105M (according to Yahoo), Total $605M after offering
    8. Current free cash flow is -282M (according to Yahoo)
    9. ASND lost $384M ($6.73/share) in FY21 and $106M ((1.86) in 4Q21.

    Is the Bond offering a good deal for the shareholders?
  • L
    Lookingforatenbagger
    Calling all Wall Street Stock Mavens. Which Stock price will be higher on 6/30/22, or 9/30/22 or 12/31/22 OPKO or ASND. I first asked the question on Pie Day and didn't get an answer.

    Index/Stock…03/14/22.....Now.....Change....% gain
    OPKO…….……....3.05…….....3.45........0.40.......13.1%
    ASND………...102.64......114.28.....11.64…….11.3%
  • L
    Lookingforatenbagger
    SEC filing: On March 30, 2022, an exercise window closed for the Company’s outstanding warrants exercisable for the Company’s ordinary shares, nominal value DKK 1. In connection with the exercises of certain of such warrants during this exercise window, the Company registered aggregate share capital increases of nominal DKK 20,709 with the Danish Business Authority, corresponding to an aggregate increase in the Company’s share capital to nominal DKK 56,958,391 through the issuance of 20,709 ordinary shares against average cash consideration of approximately USD $20.69 per share, based on the DKK-USD exchange rate on March 30, 2022. The Company’s articles of association were amended accordingly and are attached hereto as Exhibit 1.1.

    Not that significant in the dilution department, but a nice little $2M present of playing for the directors.
  • J
    John Perez
    Bam….lift off
  • L
    Lookingforatenbagger
    ASND hits a 2-1/2 year low of $96.97 dropping from an open high of $113. 14% in ~ an hour.
  • L
    Lookingforatenbagger
    Why is ASND setting 2-1/2 year lows after Transcon has been approved in the US while Pfizer has received a CRL? In their CC management said, "The ongoing conflict in the region surrounding Ukraine and Russia has impacted our ability to continue clinical trial activities in those countries."

    Almost half of the test subjects for Transcon were in Russia versus 18% for NGENLA. Those Russian subjects follow on studies will be stopped now and it will take years to replace them.
    Compare reported test data for NGENLA versus TransCon testing sites.
    Country.....................NGENLA............Transcon
    Israel..............................44......................0
    Greece...........................20......................8
    Bulgaria..........................11.....................6
    Poland ..........................15.....................20
    Russia...........................40.....................70 (43% of the total)*******************
    Italy.................................0.....................20
    Spain.............................28.....................0
    UK.................................12.....................0
    Germany........................13.....................6
    France...........................20.....................0
    Unknown.......................21....................31
    .....US.............................*......................*
    .....Canada.....................*......................0
    .....Argentina...................*.....................0
    .....Columbia...................*.....................0
    .....Mexico.......................*.....................0
    .....Australia...................*......................*
    .....New Zealand............*......................*
    .....Korea.......................*.......................0
    .....Taiwan.....................*.......................0
    .....India......................,..*......................0
    .....Georgia....................*.......................**************************
    .....Ukraine....................*.......................**************************
    .....Belarus....................*......................0*************************
    .....Armenia...................0......................*
    Total.............................224................161
    Total countries..............21....................14
    Total testing sites..........84....................33
  • S
    Sonu
    Why is this tanking so hard after earnings?
  • m
    manson
    Ascendis vs opko
    Ascendis as of q4 December 2019, showed 2.51 million in revenue and a loss of 1.68 per share.

    Opko pulls in over 10x that in revenue

    Yet Ascendis is over 130 bucks Ascendis stabding at 6X market cap as OPK.
    so what is the best stock?
  • S
    Serotype
    Launch of long acting growth hormone:
    PDUFA date for the long acting growth hormone is 6/25/21 but FDA inspection of manufacturing facilities may not be completed by this time. Ascendis mentioned in their recent call that they are trying to implement "innovative ways" to expedite the inspection process, wording that concerns me a bit.
    Another concern is that my understanding is that they are still negotiating the label with the FDA.
    I am not very familiar with FDA process but it looks like this is too close to planned launch time to be still working with FDA on inspections and on label.

    Appreciate any thoughts by someone who knows better.
    Bullish
  • A
    Aladdin
    Clearly, not a widely followed company but how is this 7B on 1M in sales...?

    Their pipeline has Zero guarantees
    Bearish
  • P
    Pikachu
    NovoCure Limited
    Remember what I said? under $60 you should buy with closed eyes...once this puppy is moving it's moving FAST. My top position in biotech / med tech followed by $ARWR and $ASND. Invest in disruptors, PLATFORM based biotechs with good vision and leadership. Pps will follow.
  • C
    Christopher
    Not looking good premarket... should I stay or should I sell my stocks
  • J
    Jackie
    ASND appears to have run out of steam for the short term. It is in an over bought position and will surely have a major correction, I sold my position today and will watch for a reentry point to begin buyback, hopefully in the mid 80's. Possibility earlier.
  • K
    Kim
    $SRPT conversation
    From Michelle Solly:
    Keeping an eye on a new fund, launched in Aug 2019, Logos Global!

    The team is formerly of Farallon and Versant, with ~$400m AUM (from 13F)

    They had their first filing! Top positions:

    $MRTX (8.06%)
    $SRPT (7.19%)
    $ASND (6.17%)
    $AMRN (5.09%)
    $APLS (4.43%)
  • L
    Lookingforatenbagger
    It has been an interesting run on an actual disappointing 3Q19 result. I wonder how long the hedge funds will continue to support if aSND fails to hold above $110?
  • B
    Borat is Best
    the easiest put ever
  • L
    Lookingforatenbagger
    ASND hovering at support above a large gap down. Looks like the hedge funds are trying to slowly cash out.
  • P
    Pikachu
    Any bashers that come here saying but but they have only $1m in revenues...what do you expect..this was a dev stage biotech until recently. Forget about growth hormone. TransCon PTH is going to be a blockbuster. there are 200K patients Worldwide suffering from hypopara with no effective treatment. Imo Ascendis is dirt cheap here. Stellar management, good execution and pipeline progress. 2022 is full of major catalysts
    Bullish
  • S
    Stock
    How do you lose 134 Million then go UP in value by 2 Billion?? and only 1 Million in revenues this market makes no since and institutions are sitting on all the shares Boy when they go to sell and try to get out this thing will drop like a rock
Advertisement
Advertisement